MindMed Q2 net loss narrows to $5.9M; cash at $243M to fund Phase 3 in GAD

Definium Therapeutics, Inc.

Net loss of $5.9 million, down from $29.1 million in Q2 2023, primarily due to warrant fair value changes.
Cash and equivalents of $243.1 million as of June 30, 2024; plus ~$70M net from July 2024 offering, extending runway into 2027.
Completed end-of-Phase 2 meeting with FDA; first Phase 3 trial (Voyage) for MM120 ODT in GAD to start H2 2024 with topline in H1 2026.
Expanding pipeline: registrational study (Emerge) for MM120 ODT in MDD planned for H1 2025, topline H2 2026.
New USPTO patent issued covering MM120 ODT formulation and method of treatment, extending IP protection through 2041.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.